Abstract
Chronic back pain (CBP) is a disabling condition with a lifetime prevalence of 40% and a substantial socioeconomic burden. Because of the high heterogeneity of CBP, subphenotyping may be necessary to improve prediction and support personalized treatment for those with CBP. The lack of distinct cellular and molecular markers for CBP complicates the task of subphenotyping.
To investigate CBP subphenotypes, we decomposed the genetic background of CBP into a shared genetic background common to other chronic pain conditions (back, neck, hip, knee, stomach, and head pain) and unshared genetic background related only to CBP. We showed that the shared and unshared genetic backgrounds of CBP differ in their biological functions: the first one is likely to control processes mainly in nervous, immune and musculoskeletal systems underlying chronic pain development regardless its site, while the second may contribute more to local processes in spine leading to chronic pain precisely in the back. We identified 18 genes with shared impact across different chronic pain conditions and two genes that were specific for CBP. These findings may contribute to future development of targets and new biomarkers for chronic pain management.
Next, among people with CBP, we demonstrated that polygenic risk scores accounting for the shared and unshared genetic backgrounds of CBP may underpin different subphenotypes of CBP cases. These subphenotypes are characterized by varying genetic predisposition to a wide array of medical conditions and interventions such as diabetes mellitus, myocardial infarction, diagnostic endoscopic procedures, and surgery involving muscles, bones, and joints. The proposed genetic decomposition framework holds promise for investigating the genetic underpinnings of other heterogeneous diseases.
Author Summary Chronic back pain (CBP) is a prevalent disabling health problem with heterogeneous clinical presentation and natural history. This may contribute to generic pain treatment approaches not sufficiently effective when prescribed for patients with certain characteristics. Development of more personalized treatment is needed, and may benefit from a deep understanding of CBP biology, such as genomics. It is known that chronic pain is under the control of both environmental and genetic background. Here we applied bioinformatic methods to study the genetic background of CBP decomposed into two parts: a shared one common to six distinct chronic pain types, and unshared, which is specific to CBP. This approach allowed us to identify more genes potentially involved in CBP development. Among them 18 belong to the shared genetic background contributing to development of chronic pain in general, and two are specific for CBP. We demonstrate that these two parts of the genetic background of CBP are associated with distinct biological pathways and underlie predisposition to different medical states and procedures, involving diabetes, myocardial infarction, and musculoskeletal surgery. Decomposition of CBP genetic background into shared and unshared may provide a better understanding of mechanisms of CBP and facilitate development of personalized pain treatment.
Competing Interest Statement
YSA is a cofounder and a co-owner of PolyOmica and PolyKnomics, private organizations providing services, research, and development in the field of computational and statistical genomics. The other authors declare that they have no competing interests.
Funding Statement
Funding: IVZ, YAT, GRS, and AVK were supported by the budget project of the Institute of Cytology and Genetics FWNR-2022-0020. The work of TIA and EEE was supported by the Russian Science Foundation (grant #22-15-20037) and Government of the Novosibirsk region. Acknowledgements: The work of ANT is an output of a research project implemented as part of the Research Program at the MSU Institute for Artificial Intelligence. FMKW was supported by Versus Arthritis, grant #22467.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the source data were prodused prior to initiation of the current study and were provided by UK Biobank under projects #18219 and #59345. UK Biobank publically provide anonymized data under special request https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The project code used for performing analysis is currently in open access. All the summary-level data produced in the course of this work will be available for download via the link to our site after publication of the article.
